Table 4 Univariate response analysis of metagenes stratified by subtype
From: Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
Variable a | Odds ratio | P -value |
|---|---|---|
(95% CI) | ||
Basal-like n = 205 (pr = 72, nr = 133) | ||
 B/P | 1.26 (0.95-1.68) | 0.12 |
 T/NK | 1.53 (0.93-2.51) | 0.09 |
 M/D | 1.66 (1.15-2.39) | 0.007 |
Claudin-low n = 47 (pr = 17, nr = 30) | ||
 B/P | 1.92 (1.10-3.34) | 0.02 |
 T/NK | 2.08 (0.80-5.47) | 0.14 |
 M/D | 1.11 (0.43-2.86) | 0.82 |
HER2-E n = 72 (pr = 26, nr = 46) | ||
 B/P | 1.31 (0.84-2.04) | 0.23 |
 T/NK | 0.83 ( 0.36-1.92) | 0.67 |
 M/D | 1.19 (0.54-2.59) | 0.67 |
LumB n = 133 (pr = 23, nr = 110) | ||
 B/P | 1.33 (0.93-1.89) | 0.11 |
 T/NK | 1.44 ( 0.86-2.42) | 0.16 |
 M/D | 1.71(1.01-2.91) | 0.05 |
LumA n = 207 (pr = 7, nr = 200) | ||
 B/P | 1.52 (0.82-2.83) | 0.19 |
 T/NK | 1.16 (0.52-2.60) | 0.72 |
 M/D | 0.93 (0.43-2.02) | 0.85 |